Skip to content

Source filing unavailable

Q4 2016 · —
Revenue—
Net Income-$7.21Mno prior Q4 2015 on fileN/M vs Q3 2016
EPS Diluted-$25.68no prior Q4 2015 on fileN/M vs Q3 2016
Operating Cash Flowderived-$9,204,000—
Free Cash Flowderived-$9,465,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q4 2015 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR